Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2021

23.04.2020 | Review

Mast Cell Activation Syndrome: A Primer for the Gastroenterologist

verfasst von: Leonard B. Weinstock, Laura A. Pace, Ali Rezaie, Lawrence B. Afrin, Gerhard J. Molderings

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Mast cell activation syndrome is thought to be a common, yet under-recognized, chronic multi-system disorder caused by inappropriate mast cell activation. Gastrointestinal symptoms are frequently reported by these patients and are often mistaken by physicians as functional gastrointestinal disorders. This syndrome can be diagnosed by the medical history and measurable biomarkers. Gastroenterologists manage diseases associated with active inflammatory cells including neutrophils, lymphocytes, macrophages, and eosinophils. The mast cell has only recently been recognized as a major player in our specialty. Gastrointestinal disorders from mast cell mediators often present with apparent irritable bowel syndrome, dyspepsia, chronic or cyclical nausea, and heartburn. Individuals with mast cell activation syndrome experience significant delays in diagnosis. The gastrointestinal symptoms are often refractory to symptom-targeted prescription medications. Beyond avoiding triggers, the best therapy is directed at modulating mast cell activation and the effects of the mediators. Many of these therapies are simple over-the-counter medications. In this article, we review mast cell function and dysfunction and the gastrointestinal symptoms, comorbid conditions, diagnosis, and management of mast cell activation syndrome. Gastroenterologists who become aware of this syndrome can dramatically improve the quality of life for their patients who previously have been labeled with a functional gastrointestinal disorder.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128:147-152PubMed Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128:147-152PubMed
2.
Zurück zum Zitat Afrin LB, Self S, Menk J, et al. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353:207-215.PubMed Afrin LB, Self S, Menk J, et al. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353:207-215.PubMed
3.
Zurück zum Zitat Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38:469-481.PubMedPubMedCentral Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38:469-481.PubMedPubMedCentral
4.
Zurück zum Zitat Hsieh FH. Gastrointestinal involvement in mast cell activation disorders. Immunol Allergy Clin North Am. 2018;38:429-441.PubMed Hsieh FH. Gastrointestinal involvement in mast cell activation disorders. Immunol Allergy Clin North Am. 2018;38:429-441.PubMed
5.
Zurück zum Zitat Frieling T, Meis K, Kolck UW, et al. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol. 2011;49:191-194.PubMed Frieling T, Meis K, Kolck UW, et al. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol. 2011;49:191-194.PubMed
6.
Zurück zum Zitat Afrin LB, Butterfield JH, Raithel M, et al. Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.PubMed Afrin LB, Butterfield JH, Raithel M, et al. Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.PubMed
7.
Zurück zum Zitat Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial Occurrence of Systemic Mast Cell Activation Disease. PLoS One. 2013;8:e76241. doi: 10.1371/journal.pone.0076241.CrossRefPubMedPubMedCentral Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial Occurrence of Systemic Mast Cell Activation Disease. PLoS One. 2013;8:e76241. doi: 10.1371/journal.pone.0076241.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, Mönnikes H. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64:573-582.PubMed Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, Mönnikes H. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64:573-582.PubMed
9.
Zurück zum Zitat Shen TC, Lin CL, Wei CC, et al. Bidirectional Association between Asthma and Irritable Bowel Syndrome: Two Population-Based Retrospective Cohort Studies. PLoS One. 2016;11:e0153911. doi: 10.1371/journal.pone.0153911.eCollection 2016.CrossRefPubMedPubMedCentral Shen TC, Lin CL, Wei CC, et al. Bidirectional Association between Asthma and Irritable Bowel Syndrome: Two Population-Based Retrospective Cohort Studies. PLoS One. 2016;11:e0153911. doi: 10.1371/journal.pone.0153911.eCollection 2016.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6:26. DOI: 10.1186/1471-230X-6-26CrossRefPubMedPubMedCentral Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6:26. DOI: 10.1186/1471-230X-6-26CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Beckers AB, Keszthelyi D, Fikree A, et al. Gastrointestinal disorders in joint hypermobility syndrome/Ehlers‐Danlos syndrome hypermobility type: A review for the gastroenterologist. Neurogastroenterol Motil. 2017;29:e13013. doi: 10.1111/nmo.13013.CrossRef Beckers AB, Keszthelyi D, Fikree A, et al. Gastrointestinal disorders in joint hypermobility syndrome/Ehlers‐Danlos syndrome hypermobility type: A review for the gastroenterologist. Neurogastroenterol Motil. 2017;29:e13013. doi: 10.1111/nmo.13013.CrossRef
12.
Zurück zum Zitat DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113:1458-1467.PubMed DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113:1458-1467.PubMed
13.
Zurück zum Zitat Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175:226-236.PubMed Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175:226-236.PubMed
14.
Zurück zum Zitat Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurolog Sci. 2014;340:99-102. Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurolog Sci. 2014;340:99-102.
15.
Zurück zum Zitat Shibao C, Arzubiaga C, Roberts LJ II, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385-390.PubMed Shibao C, Arzubiaga C, Roberts LJ II, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385-390.PubMed
16.
Zurück zum Zitat Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15:60. doi: 10.1007/s11910-015-0583-8.CrossRefPubMedPubMedCentral Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15:60. doi: 10.1007/s11910-015-0583-8.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Doherty TA, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83-88.PubMed Doherty TA, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83-88.PubMed
18.
Zurück zum Zitat Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70-76.PubMed Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70-76.PubMed
19.
Zurück zum Zitat Schofield JR, Afrin LB. Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. Am J Med Sci. 2019;357:507-511.PubMed Schofield JR, Afrin LB. Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. Am J Med Sci. 2019;357:507-511.PubMed
20.
Zurück zum Zitat Afrin LB, Khoruts A. Mast Cell Activation Disease and Microbiotic Interactions. Clin Ther. 2015;37:941-953.PubMed Afrin LB, Khoruts A. Mast Cell Activation Disease and Microbiotic Interactions. Clin Ther. 2015;37:941-953.PubMed
21.
Zurück zum Zitat Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clin Ther. 2018;40:903-917.PubMed Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clin Ther. 2018;40:903-917.PubMed
22.
Zurück zum Zitat Weinstock LB, Rezaie A, Afrin LB. The significance of mast cell activation in the era of precision medicine. Am J Gastroenterol. 2018;113:1725-1726.PubMed Weinstock LB, Rezaie A, Afrin LB. The significance of mast cell activation in the era of precision medicine. Am J Gastroenterol. 2018;113:1725-1726.PubMed
23.
Zurück zum Zitat Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-1133.PubMedPubMedCentral Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-1133.PubMedPubMedCentral
24.
Zurück zum Zitat Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: A global “consensus-2.” Diagnosis. 2020; In press. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: A global “consensus-2.” Diagnosis. 2020; In press.
25.
Zurück zum Zitat Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders? Expert Review Clin Immunol. 2019;15:639-656.PubMedPubMedCentral Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders? Expert Review Clin Immunol. 2019;15:639-656.PubMedPubMedCentral
26.
Zurück zum Zitat Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. Blood. 2013;121:1285-1295.PubMed Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. Blood. 2013;121:1285-1295.PubMed
27.
Zurück zum Zitat Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA. F1000Res. 2017;6:1889. doi: 10.12688/f1000research.12730.1.CrossRefPubMedPubMedCentral Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA. F1000Res. 2017;6:1889. doi: 10.12688/f1000research.12730.1.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat da Silva EZM, Jamur MC, et al. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62:698-738.PubMedPubMedCentral da Silva EZM, Jamur MC, et al. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62:698-738.PubMedPubMedCentral
29.
Zurück zum Zitat Vliagoftis H, Befus AD. Mast cells at mucosal frontiers. Curr Mol Med. 2005:573-589.PubMed Vliagoftis H, Befus AD. Mast cells at mucosal frontiers. Curr Mol Med. 2005:573-589.PubMed
30.
31.
Zurück zum Zitat Rizzi A, Crivellato E, Benagiano V, et al. Mast cells in human digestive tube in normal and pathological conditions. Immunol Lett. 2016;177:16-21.PubMed Rizzi A, Crivellato E, Benagiano V, et al. Mast cells in human digestive tube in normal and pathological conditions. Immunol Lett. 2016;177:16-21.PubMed
32.
Zurück zum Zitat Poglio S, De Toni Costes F, Arnaud E, et al. Adipose tissue as a dedicated reservoir of functional mast cell progenitors. Stem Cells. 2010;28:2065-2072.PubMed Poglio S, De Toni Costes F, Arnaud E, et al. Adipose tissue as a dedicated reservoir of functional mast cell progenitors. Stem Cells. 2010;28:2065-2072.PubMed
33.
Zurück zum Zitat Li Z, Liu S, Xu J, et al. Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. Immunity. 2018;49:640-53.PubMed Li Z, Liu S, Xu J, et al. Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. Immunity. 2018;49:640-53.PubMed
34.
Zurück zum Zitat Ravanbakhsh N, Kesavan A. The role of mast cells in pediatric GI disease. Clin Rev Allergy Immunol. 2019;32:338-345. Ravanbakhsh N, Kesavan A. The role of mast cells in pediatric GI disease. Clin Rev Allergy Immunol. 2019;32:338-345.
35.
Zurück zum Zitat Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol. 2018;54:353-365.PubMed Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol. 2018;54:353-365.PubMed
36.
Zurück zum Zitat Molderings GJ, Kolck UW, Scheurlen C, et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42:1045-1053.PubMed Molderings GJ, Kolck UW, Scheurlen C, et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42:1045-1053.PubMed
37.
Zurück zum Zitat Molderings GJ. The genetic basis of mast cell activation disease - looking through a glass darkly. Crit Rev Oncol Hematol, 2015;93:75-89.PubMed Molderings GJ. The genetic basis of mast cell activation disease - looking through a glass darkly. Crit Rev Oncol Hematol, 2015;93:75-89.PubMed
38.
Zurück zum Zitat Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. Brit J Haematol. 2018;180:11-23. Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. Brit J Haematol. 2018;180:11-23.
39.
Zurück zum Zitat Jakate S, Demeo M, John R, Tobin M, Keshavarzian A. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 2006;130:362-367.PubMed Jakate S, Demeo M, John R, Tobin M, Keshavarzian A. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 2006;130:362-367.PubMed
40.
Zurück zum Zitat Doyle LA, Sepehr GJ, Hamilton MJ, et al. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832-843.PubMedPubMedCentral Doyle LA, Sepehr GJ, Hamilton MJ, et al. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832-843.PubMedPubMedCentral
41.
Zurück zum Zitat Atiakshin D, Buchwalow I, Samoilova V, Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol. 2018;149:461-477.PubMed Atiakshin D, Buchwalow I, Samoilova V, Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol. 2018;149:461-477.PubMed
42.
Zurück zum Zitat Lee H, Chung H, Park JC, et al. Heterogeneity of mucosal mast cell infiltration in subgroups of patients with esophageal chest pain. Neurogastroenterol Motil. 2014;26:786-793.PubMed Lee H, Chung H, Park JC, et al. Heterogeneity of mucosal mast cell infiltration in subgroups of patients with esophageal chest pain. Neurogastroenterol Motil. 2014;26:786-793.PubMed
43.
Zurück zum Zitat Aich A, Afrin LB, Gupta K. Mast cell-mediated mechanisms of nociception. Int J Molecular Sci. 2015;16:29069-29092. Aich A, Afrin LB, Gupta K. Mast cell-mediated mechanisms of nociception. Int J Molecular Sci. 2015;16:29069-29092.
44.
Zurück zum Zitat Weinstock LB, Kaleem Z, Selby D, et al. Mast cell deposition and activation may be a new explanation for epiploic appendagitis. BMJ Case Rep. 2018;2018:bcr–2018–224689. Weinstock LB, Kaleem Z, Selby D, et al. Mast cell deposition and activation may be a new explanation for epiploic appendagitis. BMJ Case Rep. 2018;2018:bcr–2018–224689.
45.
Zurück zum Zitat Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126: 693-702.PubMed Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126: 693-702.PubMed
46.
Zurück zum Zitat Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26-37.PubMed Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26-37.PubMed
47.
Zurück zum Zitat Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil. 2016;22:181-92.PubMedPubMedCentral Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil. 2016;22:181-92.PubMedPubMedCentral
48.
Zurück zum Zitat Lobo B, Ramos L, Martínez C. Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J. 2017;5:887-897.PubMedPubMedCentral Lobo B, Ramos L, Martínez C. Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J. 2017;5:887-897.PubMedPubMedCentral
49.
Zurück zum Zitat yKlooker TK, Braak B, Koopman KE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 201;59:1213-21.PubMed yKlooker TK, Braak B, Koopman KE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 201;59:1213-21.PubMed
50.
Zurück zum Zitat Balemans D, Aguilera-Lizarraga J, Florens MV, et al. Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316:G338-9.PubMed Balemans D, Aguilera-Lizarraga J, Florens MV, et al. Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316:G338-9.PubMed
51.
Zurück zum Zitat Weinstock LW, Rezaie R, Brook JB, et al. Small intestinal bacterial overgrowth is common in mast cell activation syndrome. Am J Gastroenterol. 2019;114:pS670. Weinstock LW, Rezaie R, Brook JB, et al. Small intestinal bacterial overgrowth is common in mast cell activation syndrome. Am J Gastroenterol. 2019;114:pS670.
52.
Zurück zum Zitat Bassotti, G, Villanacci V, Nascimbeni R, et al. Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther. 2011;34:92-9.PubMed Bassotti, G, Villanacci V, Nascimbeni R, et al. Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther. 2011;34:92-9.PubMed
53.
Zurück zum Zitat Shefler I, Salamon P, Reshef T, Mor A, Mekori YA. T Cell-Induced Mast Cell Activation: A Role for Microparticles Released from Activated T Cells. J Immunol. 2010;185:4206-12.PubMed Shefler I, Salamon P, Reshef T, Mor A, Mekori YA. T Cell-Induced Mast Cell Activation: A Role for Microparticles Released from Activated T Cells. J Immunol. 2010;185:4206-12.PubMed
54.
Zurück zum Zitat Alfter K, Kügelgen Von I, Haenisch B, et al. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 2009;29:181-6.PubMed Alfter K, Kügelgen Von I, Haenisch B, et al. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 2009;29:181-6.PubMed
55.
Zurück zum Zitat Rehman Z, Rajumon M, Alam SB, et al. Prevalence and treatment of small intestinal bacterial overgrowth (SIBO) in patients with postural orthostatic tachycardia syndrome (POTS). Clin Auton Res. 2018;28:A489. Rehman Z, Rajumon M, Alam SB, et al. Prevalence and treatment of small intestinal bacterial overgrowth (SIBO) in patients with postural orthostatic tachycardia syndrome (POTS). Clin Auton Res. 2018;28:A489.
56.
Zurück zum Zitat Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr–2017–221405. Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr–2017–221405.
57.
Zurück zum Zitat Plante GE. Vascular response to stress in health and disease. Metabol Clin Experiment. 2002;51:25-30. Plante GE. Vascular response to stress in health and disease. Metabol Clin Experiment. 2002;51:25-30.
58.
Zurück zum Zitat Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8-26.PubMed Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8-26.PubMed
59.
Zurück zum Zitat Rezaie A, Raphaeal Y, Sukov R, Liu X. Ehlers-Danlos syndrome type III (EDS) and visceroptosis: getting to the bottom of this diagnosis. Am J Gastroenterolol. 2018;113:S270-1. Rezaie A, Raphaeal Y, Sukov R, Liu X. Ehlers-Danlos syndrome type III (EDS) and visceroptosis: getting to the bottom of this diagnosis. Am J Gastroenterolol. 2018;113:S270-1.
60.
Zurück zum Zitat Weinstock LB, Myers TL, Walters AS, et al. Identification and treatment of new inflammatory triggers for complex regional pain syndrome: small intestinal bacterial overgrowth and obstructive sleep apnea. A&A Case Reports. 2016;6:272-276. Weinstock LB, Myers TL, Walters AS, et al. Identification and treatment of new inflammatory triggers for complex regional pain syndrome: small intestinal bacterial overgrowth and obstructive sleep apnea. A&A Case Reports. 2016;6:272-276.
61.
Zurück zum Zitat Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:181-187.PubMed Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:181-187.PubMed
62.
Zurück zum Zitat Fikree A, Grahame R, Aktar R, et al. A prospective evaluation of undiagnosed joint hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2014;12:1680-1687.PubMed Fikree A, Grahame R, Aktar R, et al. A prospective evaluation of undiagnosed joint hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2014;12:1680-1687.PubMed
63.
Zurück zum Zitat Chang AR, Vadas P. Prevalence of Symptoms of Mast Cell Activation in Patients with Postural Orthostatic Tachycardia Syndrome and Hypermobile Ehlers-Danlos Syndrome. J Allergy Clin Immunol. 2019. AB182. Chang AR, Vadas P. Prevalence of Symptoms of Mast Cell Activation in Patients with Postural Orthostatic Tachycardia Syndrome and Hypermobile Ehlers-Danlos Syndrome. J Allergy Clin Immunol. 2019. AB182.
64.
Zurück zum Zitat Molderings GJ, Brettner S, Homann J, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011 Mar 22;4:10. doi: 10.1186/1756-8722-4-10.CrossRef Molderings GJ, Brettner S, Homann J, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011 Mar 22;4:10. doi: 10.1186/1756-8722-4-10.CrossRef
65.
Zurück zum Zitat Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564-1569.PubMedPubMedCentral Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564-1569.PubMedPubMedCentral
66.
Zurück zum Zitat Valent PA, Bonadonna PB, Hartmann KC, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180:44-51.PubMedPubMedCentral Valent PA, Bonadonna PB, Hartmann KC, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180:44-51.PubMedPubMedCentral
67.
Zurück zum Zitat Vysniauskaite M, Hertfelder H-J, Oldenburg J, et al. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS One. 2015;10(4):e0124912. doi: 10.1371/journal.pone.0124912.CrossRefPubMedPubMedCentral Vysniauskaite M, Hertfelder H-J, Oldenburg J, et al. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS One. 2015;10(4):e0124912. doi: 10.1371/journal.pone.0124912.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7:1097-1106.PubMed Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7:1097-1106.PubMed
69.
Zurück zum Zitat Molderings GJ, Haenisch B, Brettner S, et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedebergs Arch Pharmacol. 2016;389:671-694.PubMedPubMedCentral Molderings GJ, Haenisch B, Brettner S, et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedebergs Arch Pharmacol. 2016;389:671-694.PubMedPubMedCentral
70.
Zurück zum Zitat McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66:1241-51.PubMed McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66:1241-51.PubMed
71.
Zurück zum Zitat Kamphuis JBJ, Guiard B, Leveque M, et al. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2020;158:652-63.PubMed Kamphuis JBJ, Guiard B, Leveque M, et al. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2020;158:652-63.PubMed
72.
Zurück zum Zitat Hagel AF, Layritz CM, Hagel WH, et al. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn-Schmiedebergs Arch Pharmacol. 2013;386:789-793.PubMed Hagel AF, Layritz CM, Hagel WH, et al. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn-Schmiedebergs Arch Pharmacol. 2013;386:789-793.PubMed
73.
Zurück zum Zitat Theoharides TC, Bielory L. Mast cells and mast cell mediators as targets of dietary supplements. Ann Allergy Asthma Immunol. 2004;93:S24-34.PubMed Theoharides TC, Bielory L. Mast cells and mast cell mediators as targets of dietary supplements. Ann Allergy Asthma Immunol. 2004;93:S24-34.PubMed
74.
Zurück zum Zitat Liu Z-Q, Li X-X, Qiu S-Q, et al. Vitamin D contributes to mast cell stabilization. Allergy. 2017; 72:1184-1192.PubMed Liu Z-Q, Li X-X, Qiu S-Q, et al. Vitamin D contributes to mast cell stabilization. Allergy. 2017; 72:1184-1192.PubMed
77.
Zurück zum Zitat Hamilton W, Gallagher A, Thomas J, White P. Risk markers for both chronic fatigue and irritable bowel syndromes: A prospective case-control study in primary care. Psychol Med. 2009;39:1913-21.PubMed Hamilton W, Gallagher A, Thomas J, White P. Risk markers for both chronic fatigue and irritable bowel syndromes: A prospective case-control study in primary care. Psychol Med. 2009;39:1913-21.PubMed
78.
Zurück zum Zitat Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541-6.PubMed Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541-6.PubMed
79.
Zurück zum Zitat Nickel JC, Tripp DA, Pontari M, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urology. 2010;184:1358–63. Nickel JC, Tripp DA, Pontari M, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urology. 2010;184:1358–63.
80.
Zurück zum Zitat Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theoharides TC. Mast cell and substance p-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. Urology. 1996;47:436-8.PubMed Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theoharides TC. Mast cell and substance p-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. Urology. 1996;47:436-8.PubMed
Metadaten
Titel
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist
verfasst von
Leonard B. Weinstock
Laura A. Pace
Ali Rezaie
Lawrence B. Afrin
Gerhard J. Molderings
Publikationsdatum
23.04.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06264-9

Weitere Artikel der Ausgabe 4/2021

Digestive Diseases and Sciences 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.